Skip to main content

Bradley F Boeve

From the FY2026 NIH awards this investigator leads as contact PI. The department is the award's.

FY2026 NIH rank #57
  • Top 1% Funded
  • Program Leader
  • Early Career
  • Diverse Portfolio

Researcher identity and coverage

Current affiliation
Not verified in ScienceDex.NIH award organizations may differ from a researcher's employer.
NIH RePORTER identity
Profile ID 9021455Search this ID in NIH RePORTER
ORCID iD
No ORCID iD on recordA researcher can add one by claiming this profile.
ScienceDex PI coverage
FY2024 through FY2026Career claims are limited to the years shown.

FY2026 award categories

  • Neurology

NIH Funding · FY2026

Linked Award Amount
$32.8M
Full award amounts, FY2026
Award Records
11
Records listing this PI
Award-Linked Rank
#57
By linked amount among FY2026 PIs
Earliest Year Loaded
2024
ScienceDex PI coverage

One scientist record

NIH portfolios and SHARE

This is the common ScienceDex page for Bradley F Boeve. NIH portfolio memberships are contextual views of this scientist, while SHARE Score, S-Index, and S-Impact describe the researcher's global sharing track record.

Review metric definitions

FY2026 NIH portfolio memberships

No institute-level portfolio release is available for this scientist and fiscal year yet. Existing award history remains unchanged above.

Researcher-associated datasets

These datasets are linked to this researcher's ShareScore identity. This does not by itself prove that an NIH portfolio funded each dataset.

No compatible author-to-dataset release is published. Dataset records are unavailable, not zero.

Award-linked funding history

Linked NIH award amounts and rank by fiscal year.

FY2026 award records by amount

NIH award records listing Bradley F Boeve as a PI. Multi-PI records show the full award amount for context.

  • 5U19AG063911-07U19Contact PI
    ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration, Cycle 2 (ALLFTD2)
    $18.7M
    award amount
  • 5U19AG071754-05U19Contact PI
    North American Prodromal Synucleinopathy Consortium for RBD, Stage 2 (NAPS2)
    $6M
    award amount
  • 5P30AG062677-08P30Contact PI
    Mayo Alzheimer's Disease Research Center
    $4.5M
    award amount
  • 5U01NS100620-10U01Co-investigator
    Longitudinal Imaging Biomarkers of Prodromal DLB
    $2.3M
    award amount
  • 3U19AG063911-07S2U19Contact PI
    ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration, Cycle 2 (ALLFTD2)
    $451.1K
    award amount
  • 3U19AG071754-05S1U19Co-investigator
    North American Prodromal Synucleinopathy Consortium for RBD, Stage 2 (NAPS2)
    $322.3K
    award amount
  • 3U19AG063911-07S1U19Contact PI
    ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration, Cycle 2 (ALLFTD2)
    $284.5K
    award amount
  • 3U19AG063911-07S3U19Contact PI
    ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration, Cycle 2 (ALLFTD2)
    $123K
    award amount
  • 3U19AG071754-05S2U19Co-investigator
    North American Prodromal Synucleinopathy Consortium for RBD, Stage 2 (NAPS2)
    $21.1K
    award amount
  • 3U19AG071754-05S3U19Co-investigator
    North American Prodromal Synucleinopathy Consortium for RBD, Stage 2 (NAPS2)
    $9.8K
    award amount

+1 more grant not shown.

Award organizations

Organizations that administered FY2026 awards listing Bradley F Boeve as a PI.

Coverage and award-record milestones

Computed from the fiscal years currently available in ScienceDex.

  1. 2024
    First NIH Award
    Mayo Clinic
  2. 2024
    $500K Cumulative Funding
  3. 2024
    $1M Cumulative Funding
  4. 2024
    $2M Cumulative Funding
  5. 2024
    Entered Top 50% Nationally
    Ranked #2712
  6. 2024
    Entered Top 25% Nationally
    Ranked #2712
  7. 2025
    $5M Cumulative Funding
  8. 2025
    Multi-Institutional Research
    Awards at 2 institutions
  9. 2025
    Program/Center Grant Leader
  10. 2026
    $10M Cumulative Funding
  11. 2026
    $25M Cumulative Funding
  12. 2026
    Entered Top 10% Nationally
    Ranked #57
  13. 2026
    Entered Top 5% Nationally
    Ranked #57
  14. 2026
    Entered Top 1% Nationally
    Ranked #57